EN

cart
Menu
Client area
Log out
Client area
Log in
Search
Search

There was an error performing your search

We could not find any results for your search

Menu

Events and news

Blog
Home > Blog > Azierta

Azierta, Azierta Foundation and Paredox Therapeutics partner to expand the clinical development of a novel oncology therapeutic in ovarian cancer

Cambridge, Massachusetts and Madrid, Spain – Paredox Therapeutics, LLC, Azierta Contract Scientific Support Consulting, S.L. and Azierta Foundation, announced today at the European Society for Medical Oncology (ESMO 2019) a partnership for co-development of Paredox’s novel therapeutic (PER-016) targeting mitochondria-based oxidative stress signaling pathways in ovarian cancer. 

 Azierta Contract Scientific Support Consulting, S.L. is a Science and Health consultancy firm committed to strengthening bonds between science and the business environment through the “Science to Business” concept. Azierta provides services in the field of medicinal products, Medical Devices, cosmetics, food supplements and biocides, offering complete solutions throughout products’ life cycle, from medical and regulatory support, to toxicology, manufacturing and distribution needs, market access and pharmacovigilance.  

 Mr. Ángel Navarro, Azierta’s CEO stated, “We are very excited to partner with Paredox in the development of this very exiting therapeutic. This is our first partnership and direct involvement in the development of an oncology asset through an innovative business model. We anticipate that Paredox’s groundbreaking science will change drug development business norms and will result in novel therapies for patients. 

 Paredox Therapeutics is a privately held pre-clinical biotechnology company based in Cambridge, Massachusetts. The company is currently developing a first-in-class oxidative stress modulator (PER-016) scheduled to enter Phase I clinical development in 1H20. This novel MOA targeted treatment approach is expected to have broad efficacy in various disease states of oxidative stress dysregulation. “This innovative partnership will allow us to expand into additional indications currently outside of our corporate strategy. This will ultimately speed up the process of reaching as many patients as possible sooner than anticipated with our exciting and potentially life-changing therapy, stated Jarrett Duncan, CEO of Paredox.  

 More information about Paredox Therapeutics and Azierta Foundation can be found onwww.ParedoxTherapeutics.com and www.Azierta.eu and www.fundacionazierta.com 

 

Media Contacts: 

 Paredox Therapeutics  

Jarrett Duncan 

George Naumov 

One Broadway, 14th floor 

Cambridge, MA 02142 

info@paredoxtherapeutics.com 

Email: j.duncan@paredoxtherapeutics.comg.naumov@paredoxtherapeutics.com  

 

Azierta Contract Scientific Support Consulting, S.L. and Azierta Foundation 

Ángel Navarro (Azierta’s CEO ) 

Eduardo Rodenas (VP Azierta Foundation) 

Via de las Dos Castillas 33 

Edificio 7 

28224 Pozuelo de Alarcon (Madrid) 

Tel. 91 277 1076 

info@azierta.com  

Back

Related posts

Accessing the EU Market: Becoming a suitable CMO for Europe...

Pharmaceutical companies are faced with the need to outsource the manufacturing processes of their products for a variety...

Read more

Azierta provides comprehensive support to obtain the European...

At Azierta, we are experts in developing turnkey projects to optimize time and resources to capitalize on European business...

Read more

Leading innovation in pharma & health

100 professionals

Over 100 professionals

500 clients

Over 500 clients

9 year experience

9 years of experience

Innovation

Leading innovation

Client oriented

100% client oriented

We are at your complete disposal for any inquiry

Thank you for getting in touch! We will contact you as soon as possible to help you out
There has been an error while submitting your form, please try again, or call us at 912 77 10 76
Schedule appointment

Schedule a video call with our field experts

schedule
We use "cookies" to improve your experience on our site. Cookies enable us to tailor messages and display ads to your interests. They also help us understand how our site is being used. By continuing to use our site you consent to use our cookies.